New Delhi: Apollo Hospitals and healthcare company Siemens Healthineers have announced a research collaboration aimed at advancing innovation in artificial intelligence (AI) and imaging technologies to improve liver disease management.
According to the partners, the research will span areas such as quantitative ultrasound imaging and AI-driven clinical solutions. The stated objective is to enhance patient care pathways across the liver disease spectrum—from early detection and risk stratification to monitoring interventions and therapy response.
This collaboration is indicated to bring together Apollo’s clinical expertise and Siemens Healthineers’ technical capabilities to develop solutions focused on early diagnosis, accurate assessment, and precise monitoring, in response to the growing burden of liver diseases in India.
Dr. Sangita Reddy, Joint Managing Director – Apollo Hospitals said, “Our collaboration with Siemens Healthineers is a transformative step in using AI to redefine non-invasive diagnostics for liver disease.
Due to diagnostic challenges and the evolving understanding of the disease, the true prevalence of MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) , may be underestimated, which poses a significant public health challenge, requiring increased awareness, early detection, and effective management strategies.
AI-driven disease progression models shall play a pivotal role in early detection of fibrosis, allowing timely interventions, cost-effective screening, and improved patient outcomes. This model shall also facilitate precision population health strategies and clinical decision support across care settings.”
“Liver disease is a growing health concern in India; it’s crucial to prioritize early diagnosis and prevention through advanced diagnostic tools, lifestyle changes, and increased awareness to reverse this trend,” said Hariharan Subramanian, Managing Director, Siemens Healthcare, Private Limited.
